First Gen Shareholders Need Antidote to Controversial 'Poison Pill'
This analytical article examines the controversial 'poison pill' provision within First Gen Corporation, highlighting its significant implications for shareholders and public institutions like the Social Security System (SSS) and Government Service Insurance System (GSIS). The author argues that this mechanism, emerging amidst a feud between Lopez cousins, functions not as a traditional anti-takeover defense against external hostile bidders, but as a conditional penalty triggered by internal management changes. Specifically, the provision appears to grant economic leverage to partner Prime Infrastructure if leadership changes, effectively penalizing governance shifts rather than protecting corporate value. The analysis criticizes the two-month delay in disclosing this material clause following a major P75-billion deal announcement, citing concerns over information asymmetry and potential billions in value impairment for institutional investors. With the Philippine Stock Exchange issuing a show-cause directive regarding the late disclosure, the piece emphasizes that the structure prioritizes control retention over shareholder interests, creating substantial governance risk and market uncertainty.
Wire timeline
First Gen Shareholders Need Antidote to Controversial 'Poison Pill'
This analytical article examines the controversial 'poison pill' provision within First Gen Corporation, highlighting its significant implications for shareholders and public institutions like the Social Security System (SSS) and Government Service Insurance System (GSIS). The author argues that this mechanism, emerging amidst a feud between Lopez cousins, functions not as a traditional anti-takeover defense against external hostile bidders, but as a conditional penalty triggered by internal management changes. Specifically, the provision appears to grant economic leverage to partner Prime Infrastructure if leadership changes, effectively penalizing governance shifts rather than protecting corporate value. The analysis criticizes the two-month delay in disclosing this material clause following a major P75-billion deal announcement, citing concerns over information asymmetry and potential billions in value impairment for institutional investors. With the Philippine Stock Exchange issuing a show-cause directive regarding the late disclosure, the piece emphasizes that the structure prioritizes control retention over shareholder interests, creating substantial governance risk and market uncertainty.
RAPPLER